The DLTs were diarrhea, rash, and hyperglycemia [18, 19], which were broadly consistent with observations from studies of other AKT inhibitors (ipatasertib and MK2206) [20, 21] and other drugs affecting the PI3K/AKT pathway [22]. Here, AKT1 is linked to Hyperglycemia.